Italia markets close in 4 hours 55 minutes

Supernus Pharmaceuticals, Inc. (0LB2.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
26,24-0,90 (-3,32%)
In data: 04:41PM BST. Mercato aperto.

Supernus Pharmaceuticals, Inc.

9715 Key West Avenue
Rockville, MD 20850
United States
301 838 2500

Impiegati a tempo pieno652

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Jack A. KhattarFounder, President, CEO, Secretary & Director1,84M2,34M1961
Mr. Timothy C. DecSenior VP & CFO704,03kN/D1959
Dr. Padmanabh P. Bhatt Ph.D.Chief Scientific Officer & Senior VP of Intellectual Property628,41k153,93k1957
Mr. Frank MottolaSenior Vice President of Quality, GMP Operations, Information Technology and Regulatory Affairs526,48k37,78k1973
Dr. Jonathan Rubin M.B.A., M.D.Senior VP of Research & Development and Chief Medical Officer662,53kN/D1961
Mr. Kevin T. Anderson Esq.Compliance OfficerN/DN/D1962
Dr. Todd Horich M.B.A., Ph.D.Senior Vice President of Marketing, Commercial Operations & Market AccessN/DN/DN/D
Mr. Taylor RaifordSenior Vice President of SalesN/DN/DN/D
Dr. Bryan A. Roecklein Ph.D.Senior Vice President of Corporate DevelopmentN/DN/DN/D
Mr. Jeff BozickSenior Vice President of Supply ChainN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.


Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Governance aziendale

L'ISS Governance QualityScore di Supernus Pharmaceuticals, Inc. al 1 giugno 2024 è 5. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 3; diritti degli azionisti: 7; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.